Insider · CIK 0001976391
Harish Shantharam
Files at CBAY (CymaBay Therapeutics, Inc.), ALXO (ALX ONCOLOGY HOLDINGS INC). First filing Aug 20, 2025, latest Aug 20, 2025.
In brief
Harish Shantharam files SEC Form 4 as CFO at ALXO (ALX ONCOLOGY HOLDINGS INC), and also at CBAY (CymaBay Therapeutics, Inc.). Since Aug 20, 2025, Harish Shantharam has reported 1 open-market buy worth $58k and 0 open-market sells worth $0, the latest filed on Aug 20, 2025.
A track record needs three past buys with six months of prices behind them; Harish Shantharam has 0, so none is measured yet.
The newest scored trade: bought $58k of ALXO on Aug 18, 2025, filed Aug 20, 2025, scored 45 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ALXO: ALX ONCOLOGY HOLDINGS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | ALXObuy ALX ONCOLOGY HOLDINGS INC | $58k 75,000 shares | - | +139% from low-56% from high |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 26, 2026 | ALXO ALX ONCOLOGY HOLDINGS INC | AGrant or award Stock option (right to buy)derivative | +303,000 | $0.00 | $0 | 303,000 | Jan 28, 2026 |
| Oct 14, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | AGrant or award Employee Stock Option (right to buy)derivative | +198,750 | $0.00 | $0 | 198,750 | Oct 16, 2025 |
| Aug 18, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | POpen-market purchase Common Stock | +75,000 | $0.78 | $58k | 75,000 | Aug 20, 2025 |
| Apr 11, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | AGrant or award Employee Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Apr 15, 2025 |
| Jan 21, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | AGrant or award Employee Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Jan 23, 2025 |
| Mar 22, 2024 | CBAY CymaBay Therapeutics, Inc. | DDisposition to issuer Common Stock | -20,125 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | CBAY CymaBay Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -360,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | CBAY CymaBay Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -74,750 | - | - | 0 | Mar 22, 2024 |
| Jan 24, 2024 | CBAY CymaBay Therapeutics, Inc. | AGrant or award Common Stock | +20,125 | $0.00 | $0 | 20,125 | Jan 26, 2024 |
| Jan 24, 2024 | CBAY CymaBay Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +74,750 | $0.00 | $0 | 74,750 | Jan 26, 2024 |
Questions about Harish Shantharam
Answered from the filings on this page, as of the latest one.
Is Harish Shantharam buying or selling?
Not in the last 12 months. Harish Shantharam's latest open-market trade on SEC Form 4 was bought $58k of ALXO on Aug 18, 2025.
How did Harish Shantharam's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Harish Shantharam has 0.
Where does Harish Shantharam file Form 4?
Harish Shantharam has filed Form 4 at ALXO (ALX ONCOLOGY HOLDINGS INC) as Chief Financial Officer; CBAY (CymaBay Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.